Step Up Podiatry CMS Scores: Specialized MIPS Advice
For independent podiatrists, a 9% cut to your hard-earned revenue isn’t just an inconvenience, it can quiet a thri...
Opening Hours: 8:30 A.M. to 8:30 P.M.
For many laboratory directors and pathology practice managers, the annual MIPS (Merit-based Incentive Payment System) cycle has often felt like an exercise in administrative endurance. However, the 2026 performance year represents a fundamental shift. With CMS pushing aggressively toward MIPS Value Pathways (MVPs) and removing several legacy quality measures, the business-as-usual approach to reporting is no longer enough to protect your Part B revenue.
The 2026 performance year introduces significant volatility. CMS has finalized the removal of several high-volume, long-standing pathology measures. This “inventory purge” forces practices to scramble, as traditional workflows that relied on these specific data points are suddenly obsolete for reporting purposes. If your practice isn’t prepared to pivot to the new Pathology MVP (ID: M1501), you risk missing the necessary data to reach the performance threshold.
The stakes remain high: to avoid a potential 9% payment reduction on Medicare Part B reimbursements, clinicians must achieve a final MIPS score of at least 75 points. Because of the “budget-neutral” nature of the program, underperformance by your practice directly impacts your bottom line.
The silver lining for 2026 is the formal launch of the Pathology MVP. Designed to align with actual diagnostic reporting and cancer protocols, the MVP framework moves away from the “pick-and-mix” style of Traditional MIPS. Instead, it offers a pre-packaged, clinically relevant set of measures, which, if managed correctly, significantly reduces the administrative burden of selecting high-scoring measures.
The move to the MVP framework isn’t just a label change; it’s a structural evolution. Under the MVP, you are no longer hunting for disparate quality measures across the entire CMS inventory.
Traditional MIPS typically requires reporting on 6 quality measures. The Pathology MVP streamlines this to 4 selected measures. Crucially, you must select at least one outcome or high-priority measure, which keeps the focus on patient impact rather than just volume.
Regardless of the pathway, the 75% data completeness threshold remains the gold standard. As noted in the QPP 2026 Guide, small practices (15 or fewer clinicians) that fail to meet this threshold risk losing significant points per measure. Ensure your LIS (Laboratory Information System) is configured to capture the correct numerator/denominator pairs for all 2026 eligible cases.
Small multispecialty groups now face stricter requirements regarding subgroup registration. If your group registers as a multispecialty entity, you may be required to break into subgroups that align with specific care teams. For pathology labs, this means clearly defining the “pathology unit” within your larger group to ensure you are reporting on relevant diagnostic workflows.
You must register for your chosen MVP through the QPP website. While the window opens early in the year, the hard deadline to select your framework is December 1, 2026. Failing to register by this date effectively disqualifies you from MVP reporting for the year.
Once you hit the registration deadline, your subgroup structure is locked. You cannot retroactively shift clinicians between reporting units to “game” the score. This makes mid-year planning for your lab’s roster absolutely critical.
The MVP registration process is unforgiving once the December 1st deadline passes. Our QPP compliance team specializes in mapping pathology-specific workflows to the new MVP framework to ensure your reporting structure is finalized and audit-ready well before the cutoff.
Schedule Your MVP Readiness Audit
The retirement of CAP 22 (Biopsy Reporting Time), CAP 38 (Prostate Cancer Reporting), and CAP 41 (Basal Cell Skin Cancer Reporting) has left a vacuum in many practices’ reporting strategies. These measures were historically “easy wins” due to high volume and clear documentation requirements. Their removal forces labs to lean into newer, more complex measures that require more robust data extraction from pathology reports.
Many remaining measures are “topped-out,” meaning their scoring benchmarks are extremely tight. Because so many practices perform well on them, there is very little margin for error. If you miss just a few cases in your data submission, your score for that measure can plummet, as there is no “easy” path to a 10/10 score.
Practices must pivot toward measures that genuinely reflect their diagnostic capabilities. For instance, Measure #397 (Melanoma Reporting) remains a cornerstone for many. Lab directors should perform a cross-walk of their current LIS outputs against the remaining 2026 list to ensure no “blind spots” exist.
Most pathology labs qualify for automatic reweighting of the Promoting Interoperability category because they are considered “hospital-based” or diagnostic-focused, often lacking the patient-facing EHR touchpoints required for standard PI reporting. According to Elation Health, this weight (usually 25%) is redistributed to other categories, usually Quality. Verify your status on the QPP portal to ensure you are not accidentally expected to report on PI.
CMS has officially removed these highly-utilized Care Coordination improvement activities. While these were popular for pathology labs, they are no longer valid for credit. You must select from the updated list of Improvement Activities (IAs) to earn your 15% category score.
A frequent audit trigger is a discrepancy between the surgical pathology report and the billed CPT code (e.g., 88305 vs. 88309). If your MIPS data extraction is tied to billing codes, but your pathologist’s narrative report suggests a different complexity level, auditors will flag this as a compliance failure.
Failed interface data extractions are the leading cause of “data completeness” failures. Perform a technical audit of your LIS mappings. Ensure that your automated extraction logic correctly filters for the updated 2026 measure specifications.
Do not wait until the end of the year to check your performance. Perform a “data scrub” in July or August. Compare your LIS output against a sample of physical reports to verify that data is flowing correctly into your registry.
Utilize specialized platforms like Patient360, Healthmonix, or the CAP Registry. These tools are built specifically to bridge the gap between complex pathology data and CMS reporting requirements. They often provide “real-time” feedback on your completeness percentage, allowing you to correct courses before the year ends.
2026 is a year of transition, not just in measures, but in the fundamental philosophy of MIPS. By embracing the Pathology MVP, aligning your LIS with the new quality inventory, and proactively auditing your data, you can move from a state of compliance anxiety to strategic optimization.
You’ve spent years building your practice, don’t let a 9% penalty diminish your hard-earned revenue. QPP provides a comprehensive MIPS management solution that handles the registry integration, data scrubbing, and CMS submission so you can focus on diagnostic excellence. So, let’s protect your reimbursements together.
Consult with an Expert TodayMost pathology labs are eligible for automatic reweighting for PI. You should confirm your specific clinician status on the QPP portal.
Yes, but CMS is clearly signaling a preference for MVPs. Reporting through the Pathology MVP is generally recommended to ensure your measures are as relevant to your practice as possible.
You will be forced to report via Traditional MIPS, which may not align with your specific workflow and could make achieving a high score more difficult.
The penalty applies to your Medicare Part B fee-for-service reimbursements.
CMS defines small practices as those with 15 or fewer MIPS-eligible clinicians. This status provides specific advantages, such as automatic PI reweighting and extra quality bonus points.
